BACKGROUND
Only 3%-5% of patients with cancer nationwide enroll in clinical trials. Although participation among patients with solid tumors has been well studied, data in the hematopoietic stem cell transplantation (HSCT) setting remain limited. We sought to (1) describe clinical trial participation rates by HSCT type;...
Tamryn Fowler, R. Brazauskas, Jinalben Patel et al.· The Journal of the National...· 0 citations
BACKGROUND
Relapse remains the leading cause of treatment failure following allogeneic hematopoietic stem cell transplantation (alloHCT) for high-risk myeloid malignancies. Epigenetic dysregulation contributes to leukemogenesis and therapeutic resistance.
OBJECTIVE
OBJECTIVE: : To investigate whether pre-transplant e...
Mohammad Alhomoud, Franco Castillo Tokumori, N. Chokr et al.· Transplantation and Cellular...· 0 citations
This review summarizes the current landscape of POC CAR T-cell manufacturing, emphasizing clinical outcomes, economic sustainability, and regulatory considerations, and discusses emerging technologies, including allogeneic CAR T-cell platforms, artificial intelligence-driven manufacturing, and in vivo gene editing, tha...
Abdulrahman Nasiri, R. El Fakih, C. Chabannon et al.· Bone Marrow Transplantation· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.